Thuy B. Tran, MD; Vijay K. Maker, MD, FACS; and Ajay V. Maker, MD, FACS, report in the July issue of the Journal of the American College of Surgeons (JACS) that the addition of adjuvant immunotherapy to chemotherapy is associated with improved survival compared with chemotherapy alone after curative-intent resection of pancreatic adenocarcinoma. Future research is warranted to match specific immunotherapy agents with susceptible patient populations to improve outcomes for this aggressive disease.
This article and all other JACS content is available at www.journalacs.org.
